NasdaqGM - Nasdaq Real Time Price USD

Nurix Therapeutics, Inc. (NRIX)

9.30

-0.35

(-3.58%)

At close: May 7 at 4:00:00 PM EDT

8.57

-0.73

(-7.85%)

Pre-Market: 4:04:53 AM EDT

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

Nurix’s DEL-AI platform uses a first-in-class DEL Foundation Model trained on the Company’s proprietary DNA encoded library data Nurix’s DEL Foundation Model can accurately predict novel binders to therapeutically relevant targets, including many targets considered undruggable, with the potential to accelerate the discovery of novel drugs SAN FRANCISCO, April 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery,

GlobeNewswire 9 days ago

NRIX
-3.58%
Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour BRAF degrader demonstrates broad activity across all three BRAF mutation classes Aurora A kinase degraders demonstrate potential to address both enzymatic and scaffolding functions and promote tumor regression in brain and small cell lung cancer models SAN FRANCISCO, April 25, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a

GlobeNewswire 12 days ago

NRIX
-3.58%
Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical applications across multiple blockbuster markets in inflammation, in both rheumatology and dermatology, including rheumatoid arthritis and atopic dermatitis Nurix to receive a $5 million milestone payment from Gilead for FDA clearance of the IND, bringing the total amount received under the 2019 collab

GlobeNewswire 20 days ago

NRIX
-3.58%
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, April 11, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on April 8, 2025, the company granted inducement awards to sixteen new employees. The grants were made pursua

GlobeNewswire 26 days ago

NRIX
-3.58%
Nurix Therapeutics First Quarter 2025 Earnings: Beats Expectations

Nurix Therapeutics ( NASDAQ:NRIX ) First Quarter 2025 Results Key Financial Results Revenue: US$18.5m (up 11% from 1Q...

Simply Wall St. 27 days ago

NRIX
-3.58%
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates

Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of 6.94% and 26.41%, respectively, for the quarter ended February 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 29 days ago

NRIX
-3.58%
Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

NX-5948 assigned the nonproprietary name “bexobrutideg”U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemiaAchieved $7M in milestones and a $15M license extension fee from ongoing collaboration with SanofiEnhanced oversight and leadership team with the appointments of Roy D. Baynes to the Board and John Northcott as chief commercial officerWell capitalized with cash and marketable securities of $549.7 million SAN FRANCISCO, April 08, 2025 (G

GlobeNewswire 29 days ago

NRIX
-3.58%
NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program

Nurix stock gains as SNY expands its partnership, licensing a research program targeting a previously untreatable transcription factor for autoimmune diseases.

Zacks last month

NRIX
-3.58%

SNY
Nurix Therapeutics, Inc. (NRIX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Nurix Therapeutics (NRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks last month

NRIX
-3.58%
Nurix Therapeutics Signs Exclusive Licensing Deal With Sanofi for Autoimmune Disease Program

Nurix Therapeutics (NRIX) said Wednesday that Sanofi (SNY) has exclusively licensed an undisclosed N

PREMIUM
MT Newswires last month

NRIX
-3.58%

SNY
Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 program Nurix DEL-AI drug discovery engine generated a drug discovery program to this previously undruggable target Nurix received a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing the total amount received by Nurix to date to $105 million Nurix is eligible for an additional $465 million in development, regulatory and commercial milesto

GlobeNewswire last month

NRIX
-3.58%
Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

SAN FRANCISCO, March 25, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that company scientists will present preclinical data from its proprietary DEL-AI platform and several degrader programs in two oral presentations and two poster presentations at the American Association for Cancer Research (AACR) 2025 Annual Meet

GlobeNewswire last month

NRIX
-3.58%
Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström Macroglobulinemia First-in-class Bruton’s tyrosine kinase (BTK) degrader NX-5948 assigned nonproprietary name “bexobrutideg” in newly named degrader class of drugs SAN FRANCISCO, March 17, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradat

GlobeNewswire last month

NRIX
-3.58%
Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors

Dr. Baynes has been a member of Nurix’s Medical Advisory Board since 2023SAN FRANCISCO, March 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, announced today the appointment of Roy D. Baynes, MB.Bch., M.Med., Ph.D., to its board of directors. Dr. Baynes, who currently serves as executive vice president and chief medical officer of

GlobeNewswire last month

NRIX
-3.58%
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates

ProQR (PRQR) delivered earnings and revenue surprises of -42.86% and 51.53%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

NRIX
-3.58%
Zymeworks (ZYME) Soars 5.4%: Is Further Upside Left in the Stock?

Zymeworks (ZYME) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks last month

NRIX
-3.58%
Nurix Therapeutics to Participate in Upcoming Investor Conferences

SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, and Hans van Houte, chief finan

GlobeNewswire 2 months ago

NRIX
-3.58%
Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

SAN FRANCISCO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in a fireside c

GlobeNewswire 2 months ago

NRIX
-3.58%
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates

Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of -11.94% and 22.55%, respectively, for the quarter ended November 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 3 months ago

NRIX
-3.58%
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th American Society of Hematology Annual Meeting Received PRIME designation from the European Medicines Agency for NX-5948 in CLL Received Fast Track designation from the U.S. FDA for NX-5948 in Waldenstrom’s Macroglobulinemia Announced the appointment of John Northcott as Chief Commercial Officer Well capitalized with cash and marketable securities of $609.6

GlobeNewswire 3 months ago

NRIX
-3.58%

Performance Overview

Return	NRIX	S&P 500 (^GSPC)
YTD	-50.64%	-4.26%
1-Year	-34.32%	+8.55%
3-Year	-2.72%	+36.57%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Nurix Therapeutics, Inc. (NRIX)

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nurix Therapeutics First Quarter 2025 Earnings: Beats Expectations

Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program

Nurix Therapeutics, Inc. (NRIX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Nurix Therapeutics Signs Exclusive Licensing Deal With Sanofi for Autoimmune Disease Program

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors

ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates

Zymeworks (ZYME) Soars 5.4%: Is Further Upside Left in the Stock?

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

Performance Overview